Fidelis Capital Partners LLC Grows Stock Position in Eli Lilly and Company (NYSE:LLY)

Fidelis Capital Partners LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,955 shares of the company's stock after purchasing an additional 776 shares during the quarter. Fidelis Capital Partners LLC's holdings in Eli Lilly and Company were worth $7,036,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the first quarter worth $40,000. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $43,000. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $48,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $2.69 during midday trading on Friday, reaching $793.34. 2,851,585 shares of the company's stock traded hands, compared to its average volume of 3,670,273. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a fifty day simple moving average of $767.03 and a two-hundred day simple moving average of $800.01. The company has a market cap of $751.88 billion, a P/E ratio of 64.55, a PEG ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.58 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Morgan Stanley reissued an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. Finally, HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.